

References

1. Fleming DM, Elliot AJ. The impact of influenza on the health and health care utilisation of elderly people. *Vaccine*. 2005;23: S1-9.
2. Cheng VC, To KK, Tse H, **Hung IF**, Yuen KY. Two years after pandemic influenza A/2009/H1N1: what have we learned. *Clin Microbiol Rev*. 2012;25: 223-63.
3. World Health Organization Media Centre. Influenza (Seasonal) Fact Sheet N° 211. March, 2014 (accessed May 11, 2015 at <http://www.who.int/mediacentre/factsheets/fs211/en/>)
4. Centres for Disease Control and Prevention HAN 00374 - Emergency Preparedness and Response. Health Advisory regarding the potential for circulation of drifted influenza A (H3N2) viruses. December 3, 2014. (accessed May 11, 2015 at <http://emergency.cdc.gov/HAN/han00374.asp>)
5. Skowronski DM, Drews SJ, Fonseca K, Charest H, Chambers C, Sabaiduc S, et al. Interim estimates of 2014/5 vaccine effectiveness against influenza A (H3N2) from Canada's sentinel physician surveillance network. *Euro Surveill* 2015;20. Pi: 21022.
6. Beigel JH, Farrar J, Han AM, Hayden FG, Hyer R, de Jong MD, et al. Avian influenza A (H5N1) infection in humans. *N Engl J Med*. 2005;353: 1374-85.
7. Chen Y, Liang W, Yang S, Wu N, Gao H, Sheng J, et al. Human infections with the emerging avian influenza A H7N9 virus from wet market poultry: clinical analysis and characterization of viral genome. *Lancet*. 2013;381: 1916-25.
8. **Hung IF**, Levin Y, To KK, Chan KH, et al. Dose sparing intradermal trivalent influenza (2010/2011) vaccination overcomes reduced immunogenicity of the 2009 H1N1 strain. *Vaccine* 2012; 30:6427-35.
9. Zhang AJ, Li C, To KK, Zhu HS, Lee AC, Li CG, **Hung IF** et al. Toll-like receptor 7 agonist imiquimod in combination with influenza vaccine expedites and augments humoral immune responses against influenza A(H1N1) pdm09 virus infection in BALB/c mice. *Clin Vaccine Immunol*. 2014;21:570-9.
10. **Hung IF**, Zhang AJ, To KK, Chan JF, Li C, Zhu HS, et al. Immunogenicity of intradermal trivalent influenza vaccine with topical imiquimod: a double blind randomized controlled trial. *Clin Infect Dis* 2014;59:1246-55.
11. **Hung IF**, Zhang AJ, To KK, Chan JF, Li P, et al. Topical imiquimod just before intradermal trivalent influenza vaccine cross protects against heterologous non-vaccine and antigenically drifted viruses: a double-blind, randomized controlled, phase 2b/3 trial. *Lancet Infectious Diseases* 2016;16:209-18
12. Thomsen LL, Topley P, Daly MG, Brett SJ, Tite JP. Imiquimod and resiquimod in a mouse model: adjuvants for DNA vaccination by particle-mediated immunotherapeutic delivery. *Vaccine*. 2004;22:1799-809.
13. Zuber AK, Bråve A, Engström G, Zuber B, Ljungberg K, Fredriksson M, et al. Topical delivery of imiquimod to a mouse model as a novel adjuvant for human immunodeficiency virus (HIV) DNA. *Vaccine*. 2004;22:1791-8.
14. Weldon WC, Zarnitsyn VG, Esser ES, Taherbhai MT, Koutsonanos DG, Vassilieva EV, et al. Effect of adjuvants on responses to skin immunization by microneedles coated with influenza subunit vaccine. *PLoS One*. 2012;7:e41501.
15. Kasturi SP, Skountzou I, Albrecht RA, et al. Programming the magnitude and persistence of antibody responses with innate immunity. *Nature* 2011; 470:543-7.